The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
GlobalData on MSN3d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...
According to DelveInsight’s analysis, the epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies such as Xenon Pharmaceutical’s ...
New weight-loss treatments are being developed to preserve or increase muscle mass while shedding pounds. Companies like Eli Lilly, Regeneron, and Roche are focusing on therapies that target proteins ...
Medpage Today on MSN5d
Two Investigational Treatments for ALS Show Glimmer of HopeThe first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback